In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021
ABSTRACT The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of Enterobacterales (Klebsiella pneumoniae and Escherichia coli) collected across six Brazilian cit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-07-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.02543-24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839645674772103168 |
|---|---|
| author | Amanda Azevedo Bittencourt Vinicius Lima Faustino Paula de Mendonça Batista Lays Paulino Leonel Marina Della Negra de Paula Thales José Polis |
| author_facet | Amanda Azevedo Bittencourt Vinicius Lima Faustino Paula de Mendonça Batista Lays Paulino Leonel Marina Della Negra de Paula Thales José Polis |
| author_sort | Amanda Azevedo Bittencourt |
| collection | DOAJ |
| description | ABSTRACT The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of Enterobacterales (Klebsiella pneumoniae and Escherichia coli) collected across six Brazilian cities during 2020–2021. Antimicrobial susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpreted following Brazilian Committee on Antimicrobial Susceptibility (BrCAST)/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Enterobacterales isolates were screened for β-lactamase genes (bla) by sequencing. The most frequent isolates identified among Enterobacterales were E. coli (n = 471; 20.9%) and K. pneumoniae (n = 453; 20.1%). Susceptibility testing showed that >99% of E. coli isolates were susceptible to colistin ([COL], n = 470; 99.8%), meropenem ([MEM], n = 468; 99.4%), IMR (n = 468; 99.4%), and ceftazidime/avibactam ([CZA], n = 468; 99.4%), whereas a high proportion of E. coli multidrug-resistant (MDR) isolates were susceptible to COL (n = 69; 98.6%), CZA (n = 67; 95.7%), MEM (n = 67; 95.7%), IMR (n = 67; 95.7%), and amikacin ([AMK], n = 66; 94.3%). Overall, K. pneumoniae isolates were most susceptible to CZA (n = 414; 91.4%) and IMR (n = 411; 90.7%) and over 86.0% of K. pneumoniae MDR isolates were susceptible to CZA (n = 268; 87.3%) and IMR (n = 265; 86.3%). This study reported that IMR was one of the most effective in vitro β-lactam–β-lactamase inhibitor combinations tested and demonstrated comparable activity to CZA and higher activity than COL against both the Enterobacterales species tested.IMPORTANCEAs new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, this study emphasizes the importance of assessing the current landscape of antimicrobial resistance to identify optimal therapeutic approaches. In this way, the publication of national data is significant for understanding local epidemiology to evaluate new drugs and make the best choice among the antimicrobials available in the hospital environment, both for critically ill patients with resistant bacterial infections. |
| format | Article |
| id | doaj-art-2b51c32dc50d4a06a1bd13baccbea8f3 |
| institution | Matheson Library |
| issn | 2165-0497 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj-art-2b51c32dc50d4a06a1bd13baccbea8f32025-07-01T13:01:37ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972025-07-0113710.1128/spectrum.02543-24In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021Amanda Azevedo Bittencourt0Vinicius Lima Faustino1Paula de Mendonça Batista2Lays Paulino Leonel3Marina Della Negra de Paula4Thales José Polis5Global Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, BrazilGlobal Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, BrazilGlobal Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, BrazilReal World Evidence, IQVIA Brazil, São Paulo, BrazilGlobal Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, BrazilGlobal Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, BrazilABSTRACT The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of Enterobacterales (Klebsiella pneumoniae and Escherichia coli) collected across six Brazilian cities during 2020–2021. Antimicrobial susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpreted following Brazilian Committee on Antimicrobial Susceptibility (BrCAST)/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Enterobacterales isolates were screened for β-lactamase genes (bla) by sequencing. The most frequent isolates identified among Enterobacterales were E. coli (n = 471; 20.9%) and K. pneumoniae (n = 453; 20.1%). Susceptibility testing showed that >99% of E. coli isolates were susceptible to colistin ([COL], n = 470; 99.8%), meropenem ([MEM], n = 468; 99.4%), IMR (n = 468; 99.4%), and ceftazidime/avibactam ([CZA], n = 468; 99.4%), whereas a high proportion of E. coli multidrug-resistant (MDR) isolates were susceptible to COL (n = 69; 98.6%), CZA (n = 67; 95.7%), MEM (n = 67; 95.7%), IMR (n = 67; 95.7%), and amikacin ([AMK], n = 66; 94.3%). Overall, K. pneumoniae isolates were most susceptible to CZA (n = 414; 91.4%) and IMR (n = 411; 90.7%) and over 86.0% of K. pneumoniae MDR isolates were susceptible to CZA (n = 268; 87.3%) and IMR (n = 265; 86.3%). This study reported that IMR was one of the most effective in vitro β-lactam–β-lactamase inhibitor combinations tested and demonstrated comparable activity to CZA and higher activity than COL against both the Enterobacterales species tested.IMPORTANCEAs new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, this study emphasizes the importance of assessing the current landscape of antimicrobial resistance to identify optimal therapeutic approaches. In this way, the publication of national data is significant for understanding local epidemiology to evaluate new drugs and make the best choice among the antimicrobials available in the hospital environment, both for critically ill patients with resistant bacterial infections.https://journals.asm.org/doi/10.1128/spectrum.02543-24antibioticsbacterial infectionsEnterobacteralesimipenem/relebactamsurveillance |
| spellingShingle | Amanda Azevedo Bittencourt Vinicius Lima Faustino Paula de Mendonça Batista Lays Paulino Leonel Marina Della Negra de Paula Thales José Polis In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021 Microbiology Spectrum antibiotics bacterial infections Enterobacterales imipenem/relebactam surveillance |
| title | In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021 |
| title_full | In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021 |
| title_fullStr | In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021 |
| title_full_unstemmed | In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021 |
| title_short | In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021 |
| title_sort | in vitro activity of imipenem relebactam and comparators against enterobacterales isolates collected in brazilian hospitals according to results from the study for monitoring antimicrobial resistance trends 2020 2021 |
| topic | antibiotics bacterial infections Enterobacterales imipenem/relebactam surveillance |
| url | https://journals.asm.org/doi/10.1128/spectrum.02543-24 |
| work_keys_str_mv | AT amandaazevedobittencourt invitroactivityofimipenemrelebactamandcomparatorsagainstenterobacteralesisolatescollectedinbrazilianhospitalsaccordingtoresultsfromthestudyformonitoringantimicrobialresistancetrends20202021 AT viniciuslimafaustino invitroactivityofimipenemrelebactamandcomparatorsagainstenterobacteralesisolatescollectedinbrazilianhospitalsaccordingtoresultsfromthestudyformonitoringantimicrobialresistancetrends20202021 AT paulademendoncabatista invitroactivityofimipenemrelebactamandcomparatorsagainstenterobacteralesisolatescollectedinbrazilianhospitalsaccordingtoresultsfromthestudyformonitoringantimicrobialresistancetrends20202021 AT layspaulinoleonel invitroactivityofimipenemrelebactamandcomparatorsagainstenterobacteralesisolatescollectedinbrazilianhospitalsaccordingtoresultsfromthestudyformonitoringantimicrobialresistancetrends20202021 AT marinadellanegradepaula invitroactivityofimipenemrelebactamandcomparatorsagainstenterobacteralesisolatescollectedinbrazilianhospitalsaccordingtoresultsfromthestudyformonitoringantimicrobialresistancetrends20202021 AT thalesjosepolis invitroactivityofimipenemrelebactamandcomparatorsagainstenterobacteralesisolatescollectedinbrazilianhospitalsaccordingtoresultsfromthestudyformonitoringantimicrobialresistancetrends20202021 |